Jaye Gardiner, a postdoctoral researcher at Fox Chase Cancer Center, has received the inaugural Black in Cancer postdoctoral fellowship, which will provide $75,000 annually for three years to support her research into pancreatic ductal adenocarcinoma.
The Bristol Myers Squibb Foundation, together with its partners, National Medical Fellowships and the American Association for Cancer Research, selected 52 physicians for its Diversity in Clinical Trials Career Development Program. These early-stage investigators are the first of 250 community-oriented clinical trialists who will be trained through the program by 2027.
Orin Bloch, a neurosurgical oncologist and professor, has been appointed as the new co-leader of UC Davis Comprehensive Cancer Center’s Biomedical Technology Program.
NYU Langone Health’s Laura and Isaac Perlmutter Cancer Center opened a new center to treat people with blood cancers, including leukemia, lymphoma, and multiple myeloma.
Lee Gerson joined the Steeplechase Cancer Center at Robert Wood Johnson University Hospital Somerset, an RWJBarnabas Health facility, as a thoracic surgeon.
The American Cancer Society and the International Association of Fire Fighters have established a long-term collaboration to help fire fighters and emergency medical service personnel with cancer detection, treatment, prevention, and patient support.
The American Association for Cancer Research and Pelotonia established a new grants program funded by The Victoria’s Secret Global Fund for Women’s Cancers to celebrate and foster innovative research in breast and gynecologic cancers.
Yale Cancer Center researchers have revealed the structure of anaplastic lymphoma kinase—a molecule that drives several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors—opening new paths for cancer treatment.
IMGN853 (mirvetuximab soravtansine) yielded positive top-line data in the pivotal phase III SORAYA trial evaluating the safety and efficacy of the monotherapy in patients with folate receptor alpha (FRα)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).
Suzanne M. Miller, a professor in the Cancer Prevention and Control Program at Fox Chase Cancer Center, developed a special edition of Translational Behavioral Medicine that summarizes several major lines of cancer prevention and control research and outlines future directions.
